RBC Capital raised the firm’s price target on Corteva (CTVA) to $85 from $74 and keeps an Outperform rating on the shares as part of a broader research note on Ag Chemicals. The firm has updated its crop yield forecast model after the April WASDE report, maintaining its belief that Ag fundamentals are improving given lower Soybean stocks/use, with WASDE still expecting farmer income to improve nearly 30% in 2025 vs 2024 given higher government payments, the analyst tells investors in a research note. Price-to-cost should be flat to positive for the company given new product offerings, cost deflation, self-help and recent Fluindapyr sales collaborations, RBC added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTVA:
- Corteva price target raised to $90 from $76 at UBS
- Corteva price target raised to $86 from $74 at BMO Capital
- Corteva’s Strong Growth Potential and Financial Resilience Earns Buy Rating with Raised Target Price
- Corteva price target raised to $75 from $70 at Barclays
- Corteva price target raised to $82 from $79 at Wells Fargo